Patents by Inventor Soo Bong CHA

Soo Bong CHA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IMIDAZOPYRIMIDINE AND IMIDAZOTRIAZINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
    Publication number: 20210300933
    Abstract: The present disclosure provides a compound of Chemical Formula (1) or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same: wherein X, Z, R1 and R2 are as defined in the specification. The compound of Chemical Formula (1) or pharmaceutically acceptable salt thereof acts as a positive allosteric modulator of metabotropic glutamate receptor subtype 5 (mGluR5), thereby being useful in the prevention or treatment of disorder mediated by glutamate dysfunction and mGluR5.
    Type: Application
    Filed: June 1, 2021
    Publication date: September 30, 2021
    Inventors: Chun Eung PARK, Young Koo JANG, Yong Je SHIN, Ji Yeon KIM, Seung Mo HAM, Yong Gil KIM, Hye Kyung MIN, Soo Bong CHA, Hyo Jun JUNG, Ju Young LEE, Seung Nam HAN, Jin Yong CHUNG, Eun Ju CHOI, Chan Mi JOUNG, Jong Sil PARK, Ji Won LEE, Nahm Ryune CHO, Eun Ju RYU, Cheol Young MAENG
  • Imidazopyrimidine and imidazotriazine derivative, and pharmaceutical composition comprising the same
    Patent number: 11046702
    Abstract: The present disclosure provides a compound of Chemical Formula (1) or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same: wherein X, Z, R1 and R2 are as defined in the specification. The compound of Chemical Formula (1) or pharmaceutically acceptable salt thereof acts as a positive allosteric modulator of metabotropic glutamate receptor subtype 5 (mGluR5), thereby being useful in the prevention or treatment of disorder mediated by glutamate dysfunction and mGluR5.
    Type: Grant
    Filed: April 17, 2020
    Date of Patent: June 29, 2021
    Assignee: SK BIOPHARMACEUTICALS CO., LTD.
    Inventors: Chun Eung Park, Young Koo Jang, Yong Je Shin, Ji Yeon Kim, Seung Mo Ham, Yong Gil Kim, Hye Kyung Min, Soo Bong Cha, Hyo Jun Jung, Ju Young Lee, Seung Nam Han, Jin Yong Chung, Eun Ju Choi, Chan Mi Joung, Jong Sil Park, Ji Won Lee, Nahm Ryune Cho, Eun Ju Ryu, Cheol Young Maeng
  • IMIDAZOPYRIMIDINE AND IMIDAZOTRIAZINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
    Publication number: 20200277298
    Abstract: The present disclosure provides a compound of Chemical Formula (1) or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same: wherein X, Z, R1 and R2 are as defined in the specification. The compound of Chemical Formula (1) or pharmaceutically acceptable salt thereof acts as a positive allosteric modulator of metabotropic glutamate receptor subtype 5 (mGluR5), thereby being useful in the prevention or treatment of disorder mediated by glutamate dysfunction and mGluR5.
    Type: Application
    Filed: April 17, 2020
    Publication date: September 3, 2020
    Inventors: Chun Eung PARK, Young Koo JANG, Yong Je SHIN, Ji Yeon KIM, Seung Mo HAM, Yong Gil KIM, Hye Kyung MIN, Soo Bong CHA, Hyo Jun JUNG, Ju Young LEE, Seung Nam HAN, Jin Yong CHUNG, Eun Ju CHOI, Chan Mi JOUNG, Jong Sil PARK, Ji Won LEE, Nahm Ryune CHO, Eun Ju RYU, Cheol Young MAENG
  • IMIDAZOPYRIMIDINE AND IMIDAZOTRIAZINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
    Publication number: 20190031669
    Abstract: The present disclosure provides a compound of Chemical Formula (1) or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same: wherein X, Z, R1 and R2 are as defined in the specification. The compound of Chemical Formula (1) or pharmaceutically acceptable salt thereof acts as a positive allosteric modulator of metabotropic glutamate receptor subtype 5 (mGluR5), thereby being useful in the prevention or treatment of disorder mediated by glutamate dysfunction and mGluR5.
    Type: Application
    Filed: September 28, 2018
    Publication date: January 31, 2019
    Inventors: Chun Eung PARK, Young Koo JANG, Yong Je SHIN, Ji Yeon KIM, Seung Mo HAM, Yong Gil KIM, Hye Kyung MIN, Soo Bong CHA, Hyo Jun JUNG, Ju Young LEE, Seung Nam HAN, Jin Yong CHUNG, Eun Ju CHOI, Chan Mi JOUNG, Jong Sil PARK, Ji Won LEE, Nahm Ryune CHO, Eun Ju RYU, Cheol Young MAENG
  • Imidazopyrimidine and imidazotriazine derivative, and pharmaceutical composition comprising the same
    Patent number: 10100057
    Abstract: The present disclosure provides a compound of Chemical Formula (1) or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same: wherein X, Z, R1 and R2 are as defined in the specification. The compound of Chemical Formula (1) or pharmaceutically acceptable salt thereof acts as a positive allosteric modulator of metabotropic glutamate receptor subtype 5 (mGluR5), thereby being useful in the prevention or treatment of disorder mediated by glutamate dysfunction and mGluR5.
    Type: Grant
    Filed: July 31, 2017
    Date of Patent: October 16, 2018
    Assignee: SK BIOPHARMACEUTICALS CO., LTD.
    Inventors: Chun Eung Park, Young Koo Jang, Yong Je Shin, Ji Yeon Kim, Seung Mo Ham, Yong Gil Kim, Hye Kyung Min, Soo Bong Cha, Hyo Jun Jung, Ju Young Lee, Seung Nam Han, Jin Yong Chung, Eun Ju Choi, Chan Mi Joung, Jong Sil Park, Ji Won Lee, Nahm Ryune Cho, Eun Ju Ryu, Cheol Young Maeng
  • IMIDAZOPYRIMIDINE AND IMIDAZOTRIAZINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
    Publication number: 20170349597
    Abstract: The present disclosure provides a compound of Chemical Formula (1) or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same: wherein X, Z, R1 and R2 are as defined in the specification. The compound of Chemical Formula (1) or pharmaceutically acceptable salt thereof acts as a positive allosteric modulator of metabotropic glutamate receptor subtype 5 (mGluR5), thereby being useful in the prevention or treatment of disorder mediated by glutamate dysfunction and mGluR5.
    Type: Application
    Filed: July 31, 2017
    Publication date: December 7, 2017
    Inventors: Chun Eung PARK, Young Koo JANG, Yong Je SHIN, Ji Yeon KIM, Seung Mo HAM, Yong Gil KIM, Hye Kyung MIN, Soo Bong CHA, Hyo Jun JUNG, Ju Young LEE, Seung Nam HAN, Jin Yong CHUNG, Eun Ju CHOI, Chan Mi JOUNG, Jong Sil PARK, Ji Won LEE, Nahm Ryune CHO, Eun Ju RYU, Cheol Young MAENG
  • Imidazopyrimidine and imidazotriazine derivative, and pharmaceutical composition comprising the same
    Patent number: 9745310
    Abstract: The present disclosure provides a compound of Chemical Formula (1) or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same: wherein X, Z, R1 and R2 are as defined in the specification. The compound of Chemical Formula (1) or pharmaceutically acceptable salt thereof acts as a positive allosteric modulator of metabotropic glutamate receptor subtype 5 (mGluR5), thereby being useful in the prevention or treatment of disorder mediated by glutamate dysfunction and mGluR5.
    Type: Grant
    Filed: February 25, 2016
    Date of Patent: August 29, 2017
    Assignee: SK BIOPHARMACEUTICALS CO., LTD.
    Inventors: Chun Eung Park, Young Koo Jang, Yong Je Shin, Ji Yeon Kim, Seung Mo Ham, Yong Gil Kim, Hye Kyung Min, Soo Bong Cha, Hyo Jun Jung, Ju Young Lee, Seung Nam Han, Jin Yong Chung, Eun Ju Choi, Chan Mi Joung, Jong Sil Park, Ji Won Lee, Nahm Ryune Cho, Eun Ju Ryu, Cheol Young Maeng
  • IMIDAZOPYRIMIDINE AND IMIDAZOTRIAZINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
    Publication number: 20160251361
    Abstract: The present disclosure provides a compound of Chemical Formula (1) or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same: wherein X, Z, R1 and R2 are as defined in the specification. The compound of Chemical Formula (1) or pharmaceutically acceptable salt thereof acts as a positive allosteric modulator of metabotropic glutamate receptor subtype 5 (mGluR5), thereby being useful in the prevention or treatment of disorder mediated by glutamate dysfunction and mGluR5.
    Type: Application
    Filed: February 25, 2016
    Publication date: September 1, 2016
    Inventors: Chun Eung PARK, Young Koo JANG, Yong Je SHIN, Ji Yeon KIM, Seung Mo HAM, Yong Gil KIM, Hye Kyung MIN, Soo Bong CHA, Hyo Jun JUNG, Ju Young LEE, Seung Nam HAN, Jin Yong CHUNG, Eun Ju CHOI, Chan Mi JOUNG, Jong Sil PARK, Ji Won LEE, Nahm Ryune CHO, Eun Ju RYU, Cheol Young MAENG